Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. Its Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacturing, distribution, sale, and marketing of generic formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, antibiotics, and multispecialty. The Contract Research Development and Manufacturing Organisation segment offers drug discovery and development services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment provides patient-focused biopharmaceutical services to address unmet medical needs in oncology and autoimmune diseases. It serves pharmaceutical, biotech, group purchasing organisations, allergists, and hospitals sectors. It sells its products through a network of dealers and distributors. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is based in Noida, India.

Revenue projections:

Revenue projections for JUBLPHARMA
Revenue projections for JUBLPHARMA

JUBLPHARMA is projected to experience a revenue decline compared to last year, a development that often leads to investor caution. The drop could negatively impact the company's bottom line, as lower revenues typically signal reduced profitability, prompting more conservative investment strategies.

Financial Ratios:

currentRatio 1.65600
forwardPE 19.83610
debtToEquity 43.86700
earningsGrowth 0.17200
revenueGrowth 0.12200
grossMargins 0.65423
operatingMargins 0.12032
trailingEps 30.12000
forwardEps 48.20000

JUBLPHARMA's current ratio of 1.656 highlights the company's ability to easily cover its short-term debt using its available cash and assets. This indicates a strong liquidity position, ensuring JUBLPHARMA is unlikely to face difficulties in meeting immediate financial obligations.
With JUBLPHARMA's Forward PE in a favorable range, the stock appears reasonably priced compared to its earnings. This suggests that it's not overpriced and there is room for growth, providing an encouraging opportunity for investors seeking future value increases.
JUBLPHARMA's positive earnings and revenue growth suggest the company is on a path to business expansion. This upward trend signals strong financial health, indicating that JUBLPHARMA is well-positioned for sustained growth in both profits and revenue.
With a forward EPS greater than its trailing EPS, JUBLPHARMA is forecasted to be more profitable this year than last. This growth expectation reflects confidence in the company's earnings potential and suggests an improving financial trajectory for the year ahead.

Price projections:

Price projections for JUBLPHARMA
Price projections for JUBLPHARMA

The current valuation of JUBLPHARMA, concerning its projections, presents no apparent risks or opportunities. This neutral outlook may lead investors to adopt a cautious approach as they await further insights into the company's performance.

Insider Transactions:

Insider Transactions for JUBLPHARMA
Insider Transactions for JUBLPHARMA


4 JUBLPHARMA stock purchases took place, with market price of 1068.9750061035156.The period under consideration did not see any buy transactions.Jubilant Pharmova Limited's current price levels are marked by increased selling, which could indicate further price drops. If this selling trend persists, the stock may continue to decline as investor confidence weakens.

Recommendation changes over time:

Recommendations trend for JUBLPHARMA
Recommendations trend for JUBLPHARMA


A recent buy bias from analysts toward JUBLPHARMA indicates strong confidence in the stock's future performance. This could encourage investors to park their money in JUBLPHARMA, viewing it as a stable and potentially rewarding investment opportunity with promising long-term growth prospects.